ZA200205265B - A novel crystalline form of N-[4-[2-[2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-glutamic acid and process therefor. - Google Patents
A novel crystalline form of N-[4-[2-[2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-glutamic acid and process therefor.Info
- Publication number
- ZA200205265B ZA200205265B ZA200205265A ZA200205265A ZA200205265B ZA 200205265 B ZA200205265 B ZA 200205265B ZA 200205265 A ZA200205265 A ZA 200205265A ZA 200205265 A ZA200205265 A ZA 200205265A ZA 200205265 B ZA200205265 B ZA 200205265B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrolo
- pyrimidin
- dihydro
- benzoyl
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18496400P | 2000-02-25 | 2000-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200205265B true ZA200205265B (en) | 2003-11-11 |
Family
ID=22679017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200205265A ZA200205265B (en) | 2000-02-25 | 2002-07-01 | A novel crystalline form of N-[4-[2-[2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-glutamic acid and process therefor. |
Country Status (36)
Country | Link |
---|---|
US (1) | US7138521B2 (fr) |
EP (1) | EP1259513B1 (fr) |
JP (1) | JP4846158B2 (fr) |
KR (1) | KR100744917B1 (fr) |
CN (1) | CN1183135C (fr) |
AR (1) | AR029471A1 (fr) |
AT (1) | ATE249462T1 (fr) |
AU (1) | AU777047B2 (fr) |
BR (1) | BR0108604A (fr) |
CA (1) | CA2400155C (fr) |
CO (1) | CO5261585A1 (fr) |
CZ (1) | CZ303772B6 (fr) |
DE (1) | DE60100750T2 (fr) |
DK (1) | DK1259513T3 (fr) |
DZ (1) | DZ3283A1 (fr) |
EA (1) | EA004684B1 (fr) |
EG (1) | EG24073A (fr) |
ES (1) | ES2206403T3 (fr) |
HK (1) | HK1051856A1 (fr) |
HR (1) | HRP20020701B1 (fr) |
HU (1) | HU229704B1 (fr) |
IL (2) | IL150480A0 (fr) |
MX (1) | MXPA02008242A (fr) |
MY (1) | MY124784A (fr) |
NO (1) | NO323422B1 (fr) |
NZ (1) | NZ519796A (fr) |
PE (1) | PE20011082A1 (fr) |
PL (1) | PL208061B1 (fr) |
PT (1) | PT1259513E (fr) |
SI (1) | SI1259513T1 (fr) |
SK (1) | SK287375B6 (fr) |
SV (1) | SV2002000321A (fr) |
TW (1) | TWI237024B (fr) |
UA (1) | UA72791C2 (fr) |
WO (1) | WO2001062760A2 (fr) |
ZA (1) | ZA200205265B (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100364993C (zh) * | 2003-05-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 培美曲噻盐及其制备方法 |
CN100364994C (zh) * | 2004-11-25 | 2008-01-30 | 重庆医药工业研究院有限责任公司 | 培美曲塞二钠的一种新晶型及其制备方法 |
CA2636596A1 (fr) * | 2005-11-04 | 2007-05-18 | James Pluda | Traitement anticancereux au saha et au pemetrexed |
EP1942907A2 (fr) * | 2005-11-04 | 2008-07-16 | Merck and Co., Inc. | Procedes d'utilisation de saha et d'erlotinibe aux fins de traitement du cancer |
US7994180B2 (en) * | 2006-08-14 | 2011-08-09 | Sicor Inc. | Processes for preparing intermediates of pemetrexed |
EP2305681A1 (fr) * | 2006-08-14 | 2011-04-06 | Sicor, Inc. | Forme cristalline de diacide de pemetrexed et son procédé de préparation |
JP2008543975A (ja) | 2006-08-14 | 2008-12-04 | シコール インコーポレイティド | 高度に純粋なペメトレキセド二酸およびその調製方法 |
DE602007011384D1 (de) * | 2006-08-14 | 2011-02-03 | Sicor Inc | Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure |
JP2010509221A (ja) * | 2006-11-03 | 2010-03-25 | ユニバーシテイ・オブ・メリーランド,ボルテイモア | 多発性骨髄腫を治療するためにsahaおよびボルテゾミブを使用する方法 |
JP2010523589A (ja) * | 2007-04-03 | 2010-07-15 | ドクター レディズ ラボラトリーズ リミテッド | ペメトレキセドの固体形 |
CN101417998B (zh) | 2007-10-24 | 2012-10-24 | 重庆医药工业研究院有限责任公司 | 一种培美曲塞盐的纯化方法 |
US20090181990A1 (en) * | 2007-12-23 | 2009-07-16 | Patel Nileshkumar S | Stable amorphous form of pemetrexed disodium |
WO2010028105A2 (fr) * | 2008-09-08 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Disodium de pemetrexed amorphe |
WO2010030598A2 (fr) * | 2008-09-11 | 2010-03-18 | Dr. Reddy's Laboratories Limited | Formulations pharmaceutiques comprenant du pemetrexed |
CN101684121B (zh) * | 2008-09-22 | 2013-04-03 | 重庆医药工业研究院有限责任公司 | 培美曲塞二酸的新晶型及其制备方法 |
CN102050825B (zh) * | 2009-11-05 | 2014-12-17 | 上海创诺制药有限公司 | 制备培美曲塞二钠2.5水结晶的方法 |
US9174991B2 (en) | 2009-11-24 | 2015-11-03 | Azad Pharmaceutical Ingredients Ag | Crystalline form of pemetrexed disodium |
CN102372719B (zh) * | 2010-08-26 | 2013-10-30 | 齐鲁制药有限公司 | 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法 |
KR101069128B1 (ko) * | 2011-03-10 | 2011-09-30 | 건일제약 주식회사 | 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법 |
US9051322B2 (en) | 2011-03-23 | 2015-06-09 | Scinopharm Taiwan, Ltd. | Process for the production of a pemetrexed salt |
ES2639639T3 (es) | 2011-03-25 | 2017-10-27 | Scinopharm Taiwan, Ltd. | Proceso para la producción de pemetrexed disódico |
ITRM20120398A1 (it) | 2012-08-08 | 2014-02-09 | Berlin Chemie Ag | Procedimento di sintesi pemetrexed e suo sale di lisina. |
CN102911176B (zh) * | 2012-10-10 | 2015-07-22 | 德州德药制药有限公司 | 一种培美曲塞二钠的制备方法 |
WO2014060959A1 (fr) * | 2012-10-17 | 2014-04-24 | Shilpa Medicare Limited | Procédé de préparation de dipotassium de pemetrexed cristallin |
US20150359898A1 (en) | 2013-02-06 | 2015-12-17 | Cipla Limited | Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes |
EP2983649A1 (fr) | 2013-04-12 | 2016-02-17 | Actavis Group PCT ehf | Formulation de pemetrexed |
KR101485243B1 (ko) * | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
JP6094388B2 (ja) * | 2013-06-07 | 2017-03-15 | ニプロ株式会社 | ペメトレキセドを含む注射用組成物 |
JP6248189B2 (ja) | 2013-06-14 | 2017-12-13 | シントン・ベスローテン・フェンノートシャップ | 安定な抗がん剤のアルギニン塩とそれを含む組成物 |
JP2016527227A (ja) | 2013-07-16 | 2016-09-08 | ドクター レディズ ラボラトリーズ リミテッド | ペメトレキセドトロメタミン塩の新規な結晶形 |
EP3040074B1 (fr) | 2013-10-03 | 2018-07-25 | Fujifilm Corporation | Préparation pharmaceutique d'injection, et procédé de fabrication de celle-ci |
NZ630292A (en) * | 2013-11-25 | 2015-02-27 | Shilpa Medicare Ltd | Process for crystalline pemetrexed dipotassium salt |
NZ630299A (en) | 2014-06-30 | 2014-11-28 | Shilpa Medicare Ltd | Pemetrexed dipotassium formulations |
CA3015436C (fr) | 2014-10-30 | 2020-07-21 | Scinopharm Taiwan, Ltd. | Formes cristallines de diacide de pemetrexed et procedes de fabrication connexes |
CN105566328B (zh) * | 2014-11-06 | 2018-04-24 | 博瑞生物医药(苏州)股份有限公司 | 培美曲塞二酸多晶型的制备方法 |
AU2018349426B2 (en) * | 2017-10-10 | 2024-01-18 | Sun Pharmaceutical Industries Limited | Intravenous infusion dosage form for pemetrexed |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO169490C (no) * | 1988-03-24 | 1992-07-01 | Takeda Chemical Industries Ltd | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater |
KR0162654B1 (ko) * | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
US5416211A (en) * | 1992-09-25 | 1995-05-16 | Eli Lilly And Company | Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines |
WO1998008382A1 (fr) * | 1996-08-30 | 1998-03-05 | Eli Lilly And Company | Antifoliques non classiques de pyrrolo[2,3-d]pyrimidine |
ZA987550B (en) * | 1997-09-26 | 2000-02-21 | Lilly Co Eli | Processes and intermediates useful to make antifolates. |
UA53742C2 (uk) * | 1997-09-26 | 2003-02-17 | Елі Ліллі Енд Компані | Спосіб одержання альдегідів, які використовують при синтезі сполук, цінних як антифолати |
AU6890800A (en) * | 1999-08-23 | 2001-03-19 | Eli Lilly And Company | A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor |
-
2001
- 2001-02-12 PL PL356423A patent/PL208061B1/pl unknown
- 2001-02-12 DK DK01906554T patent/DK1259513T3/da active
- 2001-02-12 CZ CZ20022875A patent/CZ303772B6/cs not_active IP Right Cessation
- 2001-02-12 NZ NZ519796A patent/NZ519796A/xx not_active IP Right Cessation
- 2001-02-12 DZ DZ013283A patent/DZ3283A1/fr active
- 2001-02-12 WO PCT/US2001/001229 patent/WO2001062760A2/fr active IP Right Grant
- 2001-02-12 IL IL15048001A patent/IL150480A0/xx active IP Right Grant
- 2001-02-12 CN CNB01805627XA patent/CN1183135C/zh not_active Expired - Fee Related
- 2001-02-12 EP EP01906554A patent/EP1259513B1/fr not_active Expired - Lifetime
- 2001-02-12 MX MXPA02008242A patent/MXPA02008242A/es active IP Right Grant
- 2001-02-12 SI SI200130032T patent/SI1259513T1/xx unknown
- 2001-02-12 EA EA200200905A patent/EA004684B1/ru not_active IP Right Cessation
- 2001-02-12 US US10/182,991 patent/US7138521B2/en not_active Expired - Lifetime
- 2001-02-12 AU AU34451/01A patent/AU777047B2/en not_active Ceased
- 2001-02-12 AT AT01906554T patent/ATE249462T1/de active
- 2001-02-12 PT PT01906554T patent/PT1259513E/pt unknown
- 2001-02-12 KR KR1020027011122A patent/KR100744917B1/ko not_active IP Right Cessation
- 2001-02-12 HU HU0204232A patent/HU229704B1/hu unknown
- 2001-02-12 CA CA002400155A patent/CA2400155C/fr not_active Expired - Fee Related
- 2001-02-12 SK SK1186-2002A patent/SK287375B6/sk not_active IP Right Cessation
- 2001-02-12 JP JP2001562542A patent/JP4846158B2/ja not_active Expired - Fee Related
- 2001-02-12 ES ES01906554T patent/ES2206403T3/es not_active Expired - Lifetime
- 2001-02-12 DE DE60100750T patent/DE60100750T2/de not_active Expired - Lifetime
- 2001-02-12 BR BR0108604-9A patent/BR0108604A/pt not_active Application Discontinuation
- 2001-02-21 EG EG20010167A patent/EG24073A/xx active
- 2001-02-23 CO CO01014634A patent/CO5261585A1/es not_active Application Discontinuation
- 2001-02-23 PE PE2001000194A patent/PE20011082A1/es not_active Application Discontinuation
- 2001-02-23 AR ARP010100844A patent/AR029471A1/es unknown
- 2001-02-23 TW TW090104119A patent/TWI237024B/zh not_active IP Right Cessation
- 2001-02-23 SV SV2001000321A patent/SV2002000321A/es unknown
- 2001-02-23 MY MYPI20010823A patent/MY124784A/en unknown
- 2001-12-02 UA UA2002086886A patent/UA72791C2/uk unknown
-
2002
- 2002-06-27 IL IL150480A patent/IL150480A/en not_active IP Right Cessation
- 2002-07-01 ZA ZA200205265A patent/ZA200205265B/xx unknown
- 2002-08-21 NO NO20023974A patent/NO323422B1/no not_active IP Right Cessation
- 2002-08-26 HR HR20020701A patent/HRP20020701B1/xx not_active IP Right Cessation
-
2003
- 2003-04-09 HK HK03102573A patent/HK1051856A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200205265B (en) | A novel crystalline form of N-[4-[2-[2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-glutamic acid and process therefor. | |
AU6890800A (en) | A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor | |
HK1129671A1 (en) | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6- dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
PT1155015E (pt) | Processo para a preparação de (e)-(6-¬2-¬4-(4-fluorofenil)-6- isopropil-2-¬metil(metilsulfonil)amino pirimidin-5-il vinil(4r,6s)-2,2-dimetil¬1,3 dioxan-4-il)acetato de terc-butilo | |
RS53704A (en) | Alpha-(n-sulphonamido)acetamide derivatives as betha- amyloid inhibitors | |
SG44989A1 (en) | Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman | |
IT1274571B (it) | Procedimento per la preparazione di ¬r-(r*,r*)|-5-(3-clorofenil)-3- ¬2-(3,4-dimetossifenil)-1-metil-etil|-ossazolidin-2-one | |
AU5404800A (en) | Process for the preparation of optically active n-acyl derivatives of methyl n-(2,6-dimethylphenyl)-d-alaninate | |
IL150403A0 (en) | NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | |
AU2001286586A1 (en) | Trance regulation of chondrocyte differentiation | |
BG104122A (en) | 2-{3-[4-(2-tret.-butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1 -yl]propylmercapto}pyrimidin-4-ol fumarate | |
AU2001285833A1 (en) | Process for the fermentative preparation of l-glutamic acid using coryneform bacteria | |
IL150402A0 (en) | NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | |
AU2003224361A1 (en) | Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic acid | |
AU2001296746A1 (en) | Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same | |
AU2001285881A1 (en) | Process for the fermentative preparation of d-pantothenic acid using coryneform bacteria | |
AU2002213119A1 (en) | Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same | |
AU2001241962A1 (en) | Improved process for the preparation of 3,4-dihydroxybutanoic acid and salts andlactones derived therefrom | |
IL140127A0 (en) | Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof | |
PL338759A1 (en) | Novel diethylammonic derivatives of beta-(3,5)-di-t-butyl-4-hydroxy) phenylpropionic acid aminoester | |
AU2002220571A1 (en) | (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6 -tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propio nic acid isopropyl ester, its preparation and its use | |
PL338758A1 (en) | Novel pyrolydinic salts of beta-(3,5)-di-t-butyl-4-hydroxy) phenylpropionic acid aminoester | |
GB2393185B (en) | A novel process for the preparation of 3,3'-azo-bis(6-hydroxybenzoic acid) and its derivatives | |
AU5297296A (en) | Piperidine derivatives as diuretic | |
AU2001262786A1 (en) | Use of l-2-oxothiazolidine-4-carboxylic acid for the treatment of type 2 diabetes |